Table 1.
Tests | SCA1 (n = 8) | Control 1 (n = 16) | P1 | SCA2 (n = 2) | SCA3 (n = 8) | Control 2 (n = 16) | P2 | P3 |
---|---|---|---|---|---|---|---|---|
Gender (m/f) | 4/4 | 7/9 | 0.556 | 1/1 | 7/1 | 9/7 | 0.706 | 0.142 |
Age (yrs) | 47.0 ± 9.6 | 40.3 ± 10.2 | 0.136 | 46.5 ± 16.3 | 44.1 ± 8.1 | 44.6 ± 8.5 | 1.00 | 1.00 |
Age of onset (yrs) | 39.1 ± 7.7 | - | - | 38.0 ± 14.1 | 36.8 ± 6.3 | - | - | - |
Disease duration (yrs) | 10.0 ± 4.9 | - | - | 8.5 ± 2.1 | 7.4 ± 3.7 | - | - | - |
Years of education (yrs) | 7.7 ± 5.2 | 10.6 ± 3.4 | 0.834 | 7.5 ± 2.1 | 11.0 ± 3.3 | 10.3 ± 3.8 | 0.261 | 0.742 |
ADL | 38.1 ± 15.8*** | 20.0 ± 0.00 | 0.001 | 46.0 ± 28.3* | 45.6 ± 16.7*** | 20.0 ± 0.0 | 0.013 | 0.001 |
ICARS | 34.5 ± 23.4 | - | - | 41.0 ± 25.5 | 36.8 ± 16.6 | - | - | - |
Note: ADL, activities of daily living; ICARS, international cooperative ataxia rating scale. Data are means ± SD.
P < 0.05;
**, P < 0.01;
P < 0.001.
P1, statistical difference between patients of SCA1 and control 1; P2, statistical difference between patients with SCA2 and control 2; P3, statistical difference between patients with SCA3 and control 2.